ATE380551T1 - Verwendung von brimonidine zur behandlung von dementia und morbus parkinson - Google Patents

Verwendung von brimonidine zur behandlung von dementia und morbus parkinson

Info

Publication number
ATE380551T1
ATE380551T1 AT03773199T AT03773199T ATE380551T1 AT E380551 T1 ATE380551 T1 AT E380551T1 AT 03773199 T AT03773199 T AT 03773199T AT 03773199 T AT03773199 T AT 03773199T AT E380551 T1 ATE380551 T1 AT E380551T1
Authority
AT
Austria
Prior art keywords
disease
parkinson
brimonidine
treat dementia
dementia
Prior art date
Application number
AT03773199T
Other languages
English (en)
Inventor
William Tatton
Larry Wheeler
Daniel Gil
John Donello
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE380551T1 publication Critical patent/ATE380551T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT03773199T 2002-10-08 2003-10-07 Verwendung von brimonidine zur behandlung von dementia und morbus parkinson ATE380551T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41703102P 2002-10-08 2002-10-08

Publications (1)

Publication Number Publication Date
ATE380551T1 true ATE380551T1 (de) 2007-12-15

Family

ID=32093952

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03773199T ATE380551T1 (de) 2002-10-08 2003-10-07 Verwendung von brimonidine zur behandlung von dementia und morbus parkinson

Country Status (20)

Country Link
US (1) US20040116436A1 (de)
EP (1) EP1549314B1 (de)
JP (1) JP2006504741A (de)
KR (1) KR20050056235A (de)
CN (1) CN100370988C (de)
AT (1) ATE380551T1 (de)
AU (2) AU2003279874A1 (de)
BR (1) BR0314541A (de)
CA (1) CA2501348A1 (de)
DE (1) DE60318081T2 (de)
ES (1) ES2297233T3 (de)
HK (1) HK1080408B (de)
IL (1) IL167848A (de)
MX (1) MXPA05003665A (de)
NO (1) NO20051664L (de)
NZ (1) NZ539329A (de)
PL (1) PL376347A1 (de)
RU (1) RU2332218C2 (de)
WO (1) WO2004032934A1 (de)
ZA (1) ZA200502745B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7512436B2 (en) * 2004-02-12 2009-03-31 The Regents Of The University Of Michigan Method of evaluating metabolism of the eye
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
US20100298305A1 (en) * 2008-11-26 2010-11-25 The United States Government, As Represented By The Department Of Veterans Affairs Tizanidine for the treatment of post-traumatic stress disorder and nightmares
DE102009043750A1 (de) * 2009-09-30 2011-08-04 Carl Zeiss Meditec AG, 07745 Verfahren und Vorrichtung zur Detektion von Ablagerungen im Auge
US10022341B2 (en) * 2014-12-02 2018-07-17 Yale University Methods of preventing neurodegeneration of association cortex in a mammal
RU2680526C1 (ru) * 2016-07-05 2019-02-22 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Нейропротекторное средство, обладающее свойствами антиоксиданта и донатора оксида азота
JP2019526055A (ja) * 2016-08-01 2019-09-12 コグノプティックス， インコーポレイテッド 眼組織におけるタウタンパク質を検出するためのシステムおよび方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029792A (en) * 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
BE795970A (fr) * 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US5210076A (en) * 1988-09-13 1993-05-11 Berliner David L Methods of treating Parkinson's disease using melanin
DK0828513T3 (da) * 1995-05-26 2004-04-13 Pfizer Kombinationspræparater til behandling af parkinsonisme, indeholdende selektive NMDA-antagonister
US6194415B1 (en) * 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US6841684B2 (en) * 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
US6329369B1 (en) * 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
PT1036065E (pt) * 1997-12-04 2004-09-30 Allergan Inc Derivados de imidazol substituidos com actividade do tipo agonista nos receptores alfa 2b ou 2b/2c adrenergicos
US6313172B1 (en) * 2000-04-13 2001-11-06 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
EP1365811A2 (de) * 2000-07-14 2003-12-03 Allergan, Inc. Zusammensetzungen enthaltend alpha-2-adrenergische agonisten

Also Published As

Publication number Publication date
RU2005114505A (ru) 2005-10-27
IL167848A (en) 2010-11-30
NZ539329A (en) 2007-11-30
EP1549314B1 (de) 2007-12-12
CN100370988C (zh) 2008-02-27
ZA200502745B (en) 2006-07-26
WO2004032934A1 (en) 2004-04-22
ES2297233T3 (es) 2008-05-01
PL376347A1 (en) 2005-12-27
CN1703222A (zh) 2005-11-30
US20040116436A1 (en) 2004-06-17
AU2003279874A1 (en) 2004-05-04
MXPA05003665A (es) 2005-06-08
HK1080408B (en) 2008-08-08
DE60318081D1 (de) 2008-01-24
AU2010200730A1 (en) 2010-03-18
NO20051664L (no) 2005-05-31
HK1080408A1 (en) 2006-04-28
EP1549314A1 (de) 2005-07-06
KR20050056235A (ko) 2005-06-14
BR0314541A (pt) 2005-07-26
RU2332218C2 (ru) 2008-08-27
DE60318081T2 (de) 2008-11-06
JP2006504741A (ja) 2006-02-09
CA2501348A1 (en) 2004-04-22

Similar Documents

Publication Publication Date Title
EP1484366A4 (de) Behandeltes pigment, dessen verwendung und verbindung zur behandlung von pigmenten
DE60319865D1 (de) Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen
ATE385794T1 (de) Benzothiazolderivate zur behandlung von alzheimer und parkinson
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
DE60138019D1 (de) Verwendung von triglyceriden mit mittellangen ketten zur behandlung und vorbeugung der alzheimerschen erkrankung
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
DE60027431D1 (de) Verwendung von p38 MAPK Inhibitoren in der Behandlung von Augenkrankheiten
ATE198044T1 (de) Hydroperoxeicosatetraensäure derivate enthaltende zusammensetzungen und verfahren zur verwendung zur behandlung des trockenen auges
MY140132A (en) Thiazolidin-4-one derivatives for use in the treatment of anemias
DE60325770D1 (de) Verwendung von rimexolon zur behandlung von augentrockenheit
DE60307749D1 (de) Verwendung von Flavonoid-Derivaten zur Behandlung von atopischem Ekzem
ATE435026T1 (de) Verfahren zur prävention und behandlung von diabetes mit neurturin
ATE383853T1 (de) Arylessigsäuren und verwandte verbindungen zur behandlung von alzheimer-krankheit
DE60218153D1 (de) Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges
DE50114605D1 (de) No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
DE60318081D1 (de) Verwendung von brimonidine zur behandlung von dementia und morbus parkinson
ATE289196T1 (de) Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen
DE602004026597D1 (de) Behandlung von alzheimer-krankheit und verwandten zuständen
ATE294584T1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
ATE425967T1 (de) Piperazin und piperadin-derivate fur die behandlung von neurologischen krankheiten
ATE334124T1 (de) Chinolinderivate, herstellungsprozess und verwendung zur behandlung von krankheiten, bei den s-cd23 involviert ist
DE60028538D1 (de) Kondensierte heterocyclische verbindungen und ihre verwendung zur behandlung von neurodegenerativen erkrankungen
EP4277624C0 (de) Troriluzol zur verwendung bei der behandlung der alzheimer-krankheit leichten grades
ATE390134T1 (de) (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4- fluorophenyl)ethyl)-4-piperidinemethanol oder prodrug davon zur behandlung von demenzsymptomen oder kognitiven störungen
DE602005015697D1 (de) Te zur behandlung von alzheimer-krankheit

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties